Health technology assessment is a multidisciplinary process that uses explicit methods to determine the value of a health technology at different points in its lifecycle. The purpose is to inform decision-making in order to promote an equitable, efficient, and high-quality health system.
Note 1: A health technology is an intervention developed to prevent, diagnose or treat medical conditions; promote health; provide rehabilitation; or organize healthcare delivery. The intervention can be a test, device, medicine, vaccine, procedure, program or system. (definition from the HTA Glossary)
Note 2: The process is formal, systematic, and transparent, and uses state-of-the-art methods to consider the best available evidence.
Note 3: The dimensions of value for a health technology may be assessed by examining the intended and unintended consequences of using a health technology compared to existing alternatives. These dimensions often include clinical effectiveness, safety, costs and economic implications, ethical, social, cultural and legal issues, organisational and environmental aspects, as well as wider implications for the patient, relatives, caregivers, and the population. The overall value may vary depending on the perspective taken, the stakeholders involved, and the decision context.
Note 4: HTA can be applied at different points in the lifecycle of a health technology, i.e., pre-market, during market approval, post-market, through to the disinvestment of a health technology.
The above definition was developed and agreed by INAHTA, HTAi, HTA Glossary English Editorial Board, ISPOR, RedETSA, HTAsiaLink and EUnetHTA, and published in May 2020 (see here).
Also, here is the link to the definition on the HTA Glossary.
EUnetHTA developed the HTA Core Model®, which is a methodological framework for collaborative production and sharing of HTA information.The HTA Core Model® consists of the following nine domains:
What is relative effectiveness and what are EUnetHTA Rapid Relative Effectiveness Assessments (REAs)?
Relative effectiveness can be defined as to the extent an intervention does more good than harm, compared to one or more intervention alternatives for achieving the desired results when provided under the usual circumstances of health care practice.
EUnetHTA Rapid Relative Effectiveness Assessments (REA) are health technology assessments consisting of four domains in the HTA Core Model®.
The EUnetHTA Rapid REAs include the following four domains:
- Health Problem and Current Use of the Technology
- Description and technical characteristics of technology
- Clinical Effectiveness
EUnetHTA decided to focus on these four elements because they are considered both important and transferable, i.e. usable in several countries. Besides these four domains, additional domains (i.e. economic evaluation, ethical, organisational, social and legal aspect of the introducing the technology) can be considered on a national level.
If all nine domains are covered in an assessment, it is called a full HTA. The last five domains are considered more likely to be context specific, whereas the first four domains are considered both important and transferable (i.e. usable in several countries). Therefore, in the rapid REAs EUnetHTA only focuses on the first four domains of the HTA Core Model®. At a national level, HTA-bodies may of course complement the Rapid REA with other elements that are needed in their context, for the purpose of (coverage) decision-making.
The Rapid REAs are either conducted as Joint or Collaborative Assessments; however, they both follow the same high standard quality assurance procedures. The difference between them are mainly regarding use of submission file, involvement of stakeholders, scoping meetings with the industry and centralised coordination versus decentralised (Activity Centre Department Leads). Therefore, the production processes are slightly different in the two, to allow flexibility when it is feasible. The Collaborative Assessments are only relevant in the non-pharmaceutical field. The need for the two products is related to the different characteristics of the pharmaceutical field and in the medical devices/diagnostic tests field.
The production is managed by WP4 Co-Lead Partners. WP4 stands for ‘work package 4’ of the EUnetHTA Joint Action 3. This work package is one of seven in EUnetHTA JA3 and is concerned with the actual production of assessments. The assessments should be fit for purpose, of high quality, of timely availability, and cover the whole range of health technologies. In addition, the production process is continuously refined and improved in order to best meet the needs of HTA-bodies, decision-makers and stakeholders.
The Lead Partner (LP) of WP4 is the Norwegian Institute of Public Health (NIPHNO) and is responsible for the overall coordination of the activities within the work package. There are two Co-Lead Partners who are responsible for the coordination of activities related to assessment production. These are Zorginstituut Nederland (ZIN), and Austrian Institute for Health Technology Assessment (AIHTA), Austria. ZIN is responsible for production of pharmaceutical assessments and AIHTA for assessments in non-pharmaceuticals / other technologies.
WP4 has over 60 partners from all around Europe who work together to produce the assessments through cross-border collaboration. The initiation of an assessment is either done by a EUnetHTA partner that wishes to carry out an assessment on a specific topic (usually a Collaborative Assessment for Other Technologies), or a manufacturer that initiates by contacting one of the Co-Lead Partners showing an interest to have their technology/product assessed by EUnetHTA.
The assessment team consisting of authors, co-authors and dedicated reviewers will be established after a Call for Collaboration, based on a set of criteria. These criteria will ensure among other that the team holds – expertise and knowledge in the disease area; skills and experience from previous EUnetHTA assessments; geographical spread within the team and commitment to use the report in a national setting. These criteria should also ensure a high standard quality report available in a timely manner, in addition to facilitate use in national contexts.
EUnetHTA uses Creative Commons (CC) licensing. This means that we retain copyright of published material, while allowing others to copy, distribute, and make some use of that work for non-commercial objectives. Every CC license works around the world and lasts as long as the applicable copyright lasts, since they are built on copyright. EUnetHTA uses ‘CC-BY-NC’ licenses for REAs and ‘CC-BY-SA’ licenses for guidelines. To find out more about these licenses, please read more at Creative Commons.
EUnetHTA has an error reporting and correction procedure in place. If you see a potential error in the EUnetHTA report, please contact the secretariat at firstname.lastname@example.org and report the potential error. In your email, please clearly:
- State your affiliation and contact details.
- Describe as specific as possible the potential error you discovered (mention the title of the report (and the project ID), state both the page number and the specific sentence, and mark the error).
- If applicable, please also submit a reference to a source where the correct information can be found.
For further details on the process steps and the error classification, you can consult the dedicated process flow here.
The timelines and procedures are aligned differently for pharmaceutical and non-pharmaceutical processes. For more information about the production process, please contact:
- For pharmaceutical manufacturers: WP4_pharmaceuticals@zinl.nl (ZIN)
- For non-pharmaceutical manufacturers: EUnetHTA@aihta.at (AIHTA)
For general information about Joint Production: WP4.LP_EUnetHTA.JA3@fhi.no